Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin

Cancer Immunology, Immunotherapy

Volumn 59, Issue 2, 2010, Pages 247-256

  Luo, Wei ^a   Liao, Wang Jun ^a   Ma, Li ^a   Huang, Yong Ta ^a   Shi, Min ^a   Wen, Qian ^a   Wang, Xiao Ning ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Bevacizumab; Colorectal cancer; Complementarity determining region 3; T cell receptor

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENTARITY DETERMINING REGION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HUMAN CELL; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; LIVER METABOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; FLUOROURACIL; GENES, T-CELL RECEPTOR BETA; HEMATURIA; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 71849095758     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0745-0     Document Type: Article

References (17)

1. BJ Giantonio DE Levy PJ O'dwyer NJ Meropol PJ Catalano AB Benson 3rd Eastern Cooperative Oncology Group 2006 A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200 Ann Oncol 17 1399 1403 10.1093/annonc/mdl161 1:STN:280:DC%2BD28nlt1yjtw%3D%3D 16873427 (Pubitemid 44400378)
2. MH Cohen J Gootenberg P Keegan R Pazdur 2007 FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer Oncologist 12 356 361 10.1634/theoncologist.12-3-356 1:CAS:528: DC%2BD2sXlsVSqur8%3D 17405901 (Pubitemid 46556802)
3. M Mercader BK Bodner MT Moser PS Kwon ES Park RG Manecke TM Ellis EM Wojcik D Yang RC Flanigan WB Waters WM Kast ED Kwon 2001 T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer Proc Natl Acad Sci USA 98 14565 14570 10.1073/pnas.251140998 1:CAS:528:DC%2BD3MXptFCks7g%3D 11734652 (Pubitemid 33121432)
4. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
5. National Cancer Institute (2003) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) March 31, 2003, ( http://ctep.cancer.gov ), Publish Date: August 9, 2006
6. P Soroosh F Shokri M Azizi M Jeddi-Tehrani 2003 Analysis of T-cell receptor beta chain variable gene segment usage in healthy adult responders and nonresponders to recombinant hepatitis B vaccine Scand J Immunol 57 423 431 10.1046/j.1365-3083.2003.01256.x 1:CAS:528:DC%2BD3sXksVOgtbY%3D 12753498 (Pubitemid 36577901)
7. W Luo L Ma Q Wen N Wang MQ Zhou XN Wang 2008 Analysis of the interindividual conservation of T cell receptor alpha- and beta- chain variable regions gene in the peripheral blood of patients with systemic lupus erythematosus Clin Exp Immunol 154 316 324 10.1111/j.1365-2249.2008.03770.x 1:CAS:528:DC%2BD1MXjs1Krtw%3D%3D 18811695
8. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
9. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 1:CAS:528:DC%2BD3sXms1Klu7w%3D 12890841 (Pubitemid 36910021)
10. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 10.1200/JCO.2003.10.066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D 12506171
11. H Echchakir C Asselin-Paturel G Dorothee I Vergnon D Grunenwald S Chouaib F Mami-Chouaib 1999 Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas Int J Cancer 81 205 213 10.1002/(SICI)1097-0215(19990412)81: 2<205::AID-IJC7>3.0.CO;2-M 1:CAS:528:DyaK1MXisVSltro%3D 10188720 (Pubitemid 29144748)
12. MR Rezvany MJ Tehrani C Karlsson J Lundin H Rabbani A Osterborg H Mellstedt 2006 Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia Br J Haematol 135 475 485 10.1111/j.1365-2141.2006.06324.x 1:CAS:528:DC%2BD28XhtlCju7%2FJ 16995884 (Pubitemid 44583411)
13. S Mosolits K Markovic JE Frodin L Virving CG Magnusson M Steinitz J Fagerberg H Mellstedt 2004 Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II- restricted Ep-CAM epitopes in colorectal carcinoma patients Clin Cancer Res 10 5391 5402 10.1158/1078-0432.CCR-04-0425 1:CAS:528:DC%2BD2cXmvFSltL4%3D 15328177 (Pubitemid 39100476)
14. PK Baier S Wimmenauer T Hirsch BU von Specht S von Kleist H Keller EH Farthmann 1998 Analysis of the T cell receptor variability of tumor-infiltrating lymphocytes in colorectal carcinomas Tumour Biol 19 205 212 10.1159/000030008 1:CAS:528:DyaK1cXjt1OrtLg%3D 9591047 (Pubitemid 28179553)
15. PN Akolkar B Gulwani-Akolkar M McKinley SE Fisher J Silver 1995 Comparisons of T cell receptor (TCR) V beta repertoires of lamina propria and peripheral blood lymphocytes with respect to frequency and oligoclonality Clin Immunol Immunopathol 76 155 163 10.1006/clin.1995.1110 1:STN:280: DyaK2MzjvFKjug%3D%3D 7614734
16. S Mosolits K Markovic J Fagerberg JE Frodin MR Rezvany S Kiaii H Mellstedt M Jeddi-Tehrani 2005 T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody Cancer Immunol Immunother 54 557 570 10.1007/s00262-004-0620-y 1:CAS:528:DC%2BD2MXjtlehsbw%3D 15570423 (Pubitemid 40603195)
17. B Stockinger G Kassiotis C Bourgeois 2004 Homeostasis and T cell regulation Curr Opin Immunol 16 775 779 10.1016/j.coi.2004.09.003 1:CAS:528:DC%2BD2cXptFyjt7o%3D 15511672 (Pubitemid 39423668)